Los antibióticos son el elemento fundamental de la medicina moderna y tienen un historial de reducir la carga de enfermedades infecciosas, reducir e incluso contener la mortalidad. La capacidad de tratar rápidamente las infecciones sin necesidad de identificar el patógeno causante ha permitido frenar la prevalencia de las infecciones y ha abierto varias oportunidades para la medicina moderna en forma de cirugías, trasplantes de órganos, quimioterapia y atención neonatal y pediátrica. Sin embargo, todos estos beneficios están devorando los beneficios mencionados y muchos más, lo que lleva a la OMS a advertir sobre la posibilidad de una era post-antibióticos y la carga asociada de resistencia a los antibióticos. Con la resistencia continua a los antibióticos, se prevé que para 2050, las infecciones resistentes a los antibióticos representarán más de 10 millones de muertes anuales y la carga de costos para la economía global alcanzará los 100 billones de dólares.
El manejo y la contención de la resistencia a los antibióticos es un enfoque clínico, regulatorio y económico multifacético. Tales medidas van desde mejorar el marco regulatorio, impulsar la cartera de productos, desarrollar nuevos antibióticos de espectro reducido y terapias alternativas, cambiar los objetivos terapéuticos, hasta incentivar el desarrollo de antibióticos específicos. Un aspecto importante de la estrategia antibacteriana es el desarrollo y comercialización de antibióticos específicos, es decir, fármacos antibacterianos específicos de una especie o género. Este estudio analiza los desafíos y las ventajas de este enfoque y destaca algunas recomendaciones que ayudarán a avanzar hacia la identificación de antibióticos específicos y de espectro reducido. Esta revisión no es una recopilación exhaustiva de revisiones y tendencias del mercado, pero debe utilizarse como punto destacado de algunos avances recientes y dinámicas predominantes en el área de los antibióticos dirigidos.
Las estrategias prometedoras para combatir las infecciones bacterianas resistentes pueden ser la prevención de la infección y el consiguiente riesgo de resistencia, la restauración de la línea de antibióticos mediante su implementación una combinación de medidas económicas y regulatorias, desacelerando el riesgo de resistencia al preservar el uso de antibióticos disponibles, desarrollando un enfoque novedoso de tratamientos que atacan a los microbios para reducir el potencial de infecciones resistentes, desarrollando antibióticos de espectro estrecho y específicos para especies, y desarrollando tratamientos que objetivos del huésped que los agentes microbianos.
De hecho, se ha mejorado el régimen de uso para aumentar la utilidad de los antibióticos actualmente disponibles. La mejor estrategia para contener el riesgo de resistencia; sin embargo, la falta de un mecanismo de seguimiento bien definido y la disponibilidad de recursos uniformes frenan el potencial de este enfoque. Un enfoque alternativo es el desarrollo de nuevos antibióticos como un enfoque dirigido, que ataquen así al patógeno causante y, por lo tanto, tengan un impacto reducido o incluso mínimo en la microbiota. Los antibióticos de espectro a menudo se consideran un enfoque generalizado y tosco: estos medicamentos no solo atacan al patógeno causante sino que también causan un daño visible al otro microbioma. Por lo tanto, estos tratamientos no dirigidos pueden tener consecuencias críticas en términos del eventual desarrollo de la enfermedad y, por lo tanto, urge la necesidad de una nueva generación de antibióticos y, eventualmente, la necesidad de un cambio para abordar estas preocupaciones. Algunos candidatos potenciales que recientemente han alcanzado una etapa avanzada de desarrollo clínico (antibióticos específicos para patógenos dirigidos) incluyen ridinilazol, afabicina y AR-101. Existen algunos candidatos preclínicos que son tratamientos potenciales para bacterias resistentes.
Se cree que el visible colapso de la investigación y el desarrollo de antibióticos ser el resultado de desafíos económicos y regulatorios, que se analizan más detalladamente en este informe. Se recomienda que la solución para superar estos desafíos sea un mejor ajuste y alineación de los enfoques regulatorios y económicos para el desarrollo de antibióticos. Las asociaciones público-privadas (APP) pueden ser un paso potencial para alinear el enfoque de I+D con las necesidades no satisfechas.
Perspectiva regulatoria novedosa y enfoque respectivo, como el medicamento antibiótico de población limitada La iniciativa de la Sociedad Estadounidense de Enfermedades Infecciosas también puede permitir la aprobación de medicamentos correspondientes a ensayos clínicos pequeños y económicos centrados en infecciones seleccionadas causadas por agentes altamente resistentes. Por lo tanto, se recomiendan iniciativas de este tipo para potenciar la propiedad de los antibióticos por parte de los médicos y proporcionar incentivos monetarios al reducir el costo de los ensayos clínicos. Este informe analiza exhaustivamente el estado actual y futuro del mercado general de antibióticos de amplio y estrecho espectro. Este estudio también ofrece una idea de las principales estrategias desarrolladas y desplegadas por gobiernos, médicos y fabricantes farmacéuticos en el desarrollo de antibióticos específicos. El estudio concluye con las medidas adoptadas para reducir el riesgo de una mayor resistencia a los antibióticos y recomendaciones analíticas en términos de enfoques económicos, regulatorios y clínicos que se pueden adoptar en este espacio.
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
- Way Ahead for Targeted Antibiotics: Current Status of Antibiotic Therapy and Future Roadmap, and Geography (North America, Europe, Asia Pacific, and South and Central America) Market Scope and Analysis
- Way Ahead for Targeted Antibiotics: Current Status of Antibiotic Therapy and Future Roadmap, and Geography (North America, Europe, Asia Pacific, and South and Central America) Market Size and Share
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
- GlaxoSmithKline PLC
- Pfizer Inc.
- Johnson & Johnson Inc.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi SA
- F. Hoffmann La Roche AG
- Eli Lilly & Company
- Otsuka Pharmaceutical Co. Ltd.
- AbbVie
- STADA Arzneimittel
- Cubist Pharmaceuticals
- Abbott Laboratories
- Shionogi & Co., Ltd.
- Daiichi Sankyo
- Astellas Pharma
- Sun Pharmaceutical Industries
- Lupin
- Cipla
- Top Antibiotic Startups
- Arixia Pharmaceuticals
- Acurx Pharmaceuticals
- Clemedi
- Locus Biosciences
- Bioversys
- Paratek Pharma
- Destiny Pharma
- Vedanta Biosciences
- Spero Therapeutics
- Oxford Drug Designs
- Entasis Therapeutics
- Nabriva
- Melinta Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.